MCED explains why glioblastoma (the most common primary brain tumor) patients who have favorable responses to bevacizumab (Avastin) develop early calcifications in the tumor bed while glioblastoma patients with poor responses to bevacizumab do not develop calcifications.”
http://www.vasocell.com/MCED_Home.html
MCED Discovery
http://www.vasocell.com/MCED_Discovery.html